- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02667678
5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients (HIVOL2)
5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients : HIVOL 2 Study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The aim of this study is to compare the biomarkers levels as IL-18, KIM-1 and Cystatin C for patients infected by HIV with failure in renal function at year 5. The main criterion will be a degradation of the glomerular filtration throughput measured. It will be compared to clinical scores of degradation risks of renal function for patients infected with HIV.
From 2011 to 2013, researchers realized a study called HIVOL, on the diagnostic performance of GFR (Glomerular Filtration Rate) estimators in patients infected with HIV. It lead to a publication in AIDS, retaken in the rational of recommendations of Infectious Diseases Society of America for the Chronic Renal Diseases support for patients infected with HIV.
235 patients were involved, for everyone researchers have a GFR measure (by Iohexol plasmatic clearance) and urinary and plasma samples.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Saint-etienne, Frankrike, 42100
- CHU Saint Etienne
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patient affiliated or entitled to a social security scheme
- Patient HIV infected
- Patient included in the HIVOL cohort with a GFR measure available
- Patients who have given their consent in writing
Exclusion Criteria:
- Pregnant or lactating women
- Patients treated with metformin
- Patients with a known allergy, regardless the type of allergy
- Patients with a history of thyroid dysfunction
- Any biological anomaly in the selection, which in the opinion of the investigator, may indicate a contraindication to the patient's participation in this study
- Degradation recent (not older than three months) of renal function defined as the degradation of more than 25 % GFR.
- Estimated GFR of less than 15 mL / min / 1.73m2
- History of major immediate or delayed skin reaction known to the injection of iodinated contrast medium (OMNIPAQUE®)
- Manifest thyrotoxicosis
- Hypersensitivity to the active substance or to any of the excipients (OMNIPAQUE®)
- Patient who expressed his refusal to participate in the study
- Patient justice under protection
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Cohort HIVOL, patients infected by HIV
Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2.
The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
|
Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance.
The aim of this study is to check the renal function of the patients infected by HIV.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Stage of chronic kidney disease (according to the Glomerular Filtration Rate)
Tidsram: Day 1
|
The aim of this study is to compare the level of biological biomarkers as microalbuminuria, proteinuria, KIM-1, IL-18, and Cystatin C with the level of this markers 5 years ago, for the HIVOL study performed between 2011 and 2013.
These levels will allow the researchers to have an idea concerning the renal function of the patients followed.
|
Day 1
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: GAGNEUX-BRUNON Amandine, MD, CHU Saint Etienne
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 1508032
- 2015-001455-68 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .